Dr. Ai on the Use of Hypomethylating Agents in Patients With MDS | OncLive

Dr. Ai on the Use of Hypomethylating Agents in Patients With MDS

May 7, 2018

Jing Ai, MD, physician, Levine Cancer Institute, discusses the use of hypomethylating agents in patients with myelodysplastic syndrome (MDS).

Jing Ai, MD, physician, Levine Cancer Institute, discusses the use of hypomethylating agents in patients with myelodysplastic syndrome (MDS).

The go-to regimen for patients with MDS is still hypomethylating agents, says Ai. There have not been any other recent approvals for this patient population that would replace these agents. Hypomethylating agents are used as a backbone, and a lot of clinical trials are building upon that backbone by adding targeted therapies, monoclonal antibodies, or immune-based therapies.

Levine Cancer Institute recently opened a clinical trial investigating a hypomethylating agent in combination with a PD-1 inhibitor in high-risk patients in the relapsed/refractory setting. In the field, there are different combinations such as IDH1/2 inhibitors and BCL-2 inhibitors. There are single-agent trials, states Ai, but most of them have the hypomethylating backbone.


x